{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:32:07Z","timestamp":1792798327994,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as \u201cblast-phase MPN\u201d, is the most feared disease complication, with incidence estimates of 1\u20134% for essential thrombocythemia, 3\u20137% for polycythemia vera, and 9\u201313% for primary myelofibrosis. Diagnosis of MPN-BP requires the presence of \u226520% circulating or bone marrow blasts; a lower level of excess blasts (10\u201319%) constitutes \u201caccelerated phase\u201d disease (MPN-AP). Neither \u201cintensive\u201d nor \u201cless intensive\u201d chemotherapy, by itself, secures long-term survival in MPN-BP. Large-scale retrospective series have consistently shown a dismal prognosis in MPN-BP, with 1- and 3-year survival estimates of &lt;20% and &lt;5%, respectively. Allogeneic hematopoietic stem cell transplant (AHSCT) offers the possibility of a &gt;30% 3-year survival rate and should be pursued, ideally, while the patient is still in chronic phase disease. The value of pre-transplant bridging chemotherapy is uncertain in MPN-AP while it is advised in MPN-BP; in this regard, we currently favor combination chemotherapy with venetoclax (Ven) and hypomethylating agent (HMA); response is more likely in the absence of complex\/monosomal karyotype and presence of\n                    <jats:italic>TET2<\/jats:italic>\n                    mutation. Furthermore, in the presence of an\n                    <jats:italic>IDH<\/jats:italic>\n                    mutation, the use of IDH inhibitors, either alone or in combination with Ven-HMA, can be considered. Pre-transplant clearance of excess blasts is desired but not mandated; in this regard, additional salvage chemotherapy is more likely to compromise transplant eligibility rather than improve post-transplant survival. Controlled studies are needed to determine the optimal pre- and post-transplant measures that target transplant-associated morbidity and post-transplant relapse.\n                  <\/jats:p>","DOI":"10.1038\/s41408-023-00878-8","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T23:30:37Z","timestamp":1689636637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8404","authenticated-orcid":false,"given":"Hassan","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"878_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"878_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.26751","volume":"98","author":"J Thiele","year":"2023","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, et al. The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166\u201379.","journal-title":"Am J Hematol"},{"key":"878_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737\u201340.","journal-title":"Leuk Res"},{"key":"878_CR4","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"878_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"key":"878_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25:82\u201388.","journal-title":"Leukemia"},{"key":"878_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/leu.2011.374","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012;26:1439\u201341.","journal-title":"Leukemia"},{"key":"878_CR8","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861\u20139.","journal-title":"Leukemia"},{"key":"878_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32:1189\u201399.","journal-title":"Leukemia"},{"key":"878_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0175-y","volume":"9","author":"RR Vallapureddy","year":"2019","unstructured":"Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, et al. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J. 2019;9:12.","journal-title":"Blood Cancer J"},{"key":"878_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"878_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"878_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.","journal-title":"Blood Cancer J"},{"key":"878_CR14","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"878_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00639-z","volume":"12","author":"N Gangat","year":"2022","unstructured":"Gangat N, Jadoon Y, Szuber N, Hanson CA, Wolanskyj-Spinner AP, Ketterling RP, et al. Cytogenetic abnormalities in essential thrombocythemia: clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer J. 2022;12:44.","journal-title":"Blood Cancer J"},{"key":"878_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.leu.2404500","volume":"21","author":"N Gangat","year":"2007","unstructured":"Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270\u20136.","journal-title":"Leukemia"},{"key":"878_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801\u201321.","journal-title":"Am J Hematol"},{"key":"878_CR18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018;32:1200\u201310.","journal-title":"Leukemia"},{"key":"878_CR19","doi-asserted-by":"publisher","unstructured":"Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, et al. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2022.282627.","DOI":"10.3324\/haematol.2022.282627"},{"key":"878_CR20","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1080\/10428194.2018.1441408","volume":"59","author":"LM Mollard","year":"2018","unstructured":"Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Roue I, et al. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leuk Lymphoma. 2018;59:2812\u201320.","journal-title":"Leuk Lymphoma"},{"key":"878_CR21","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008;112:1628\u201337.","journal-title":"Blood"},{"key":"878_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","volume":"70","author":"G Lancman","year":"2018","unstructured":"Lancman G, Brunner A, Hoffman R, Mascarenhas J, Hobbs G. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. Leuk Res. 2018;70:49\u201355.","journal-title":"Leuk Res"},{"key":"878_CR23","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1182\/blood-2022-157603","volume":"140","author":"AA Patel","year":"2022","unstructured":"Patel AA, Yoon JJ, Johnston H, Chen EC, Burkart M, Seijung Oh T, et al. Outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era of myeloid therapies. Blood. 2022;140:6860\u20132.","journal-title":"Blood"},{"key":"878_CR24","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1182\/blood-2021-146945","volume":"138","author":"FC Tokumori","year":"2021","unstructured":"Tokumori FC, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, et al. Different treatment approaches to blast-phase myeloproliferative neoplasms. Blood. 2021;138:3641.","journal-title":"Blood"},{"key":"878_CR25","doi-asserted-by":"crossref","unstructured":"Gangat N, Ilyas R, McCullough K, Begna KH, Al-Kali A, Patnaik MM, et al. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm. Haematologica. 2023;108:1423\u20138.","DOI":"10.3324\/haematol.2022.282019"},{"key":"878_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ajh.26186","volume":"96","author":"N Gangat","year":"2021","unstructured":"Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, et al. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases. Am J Hematol. 2021;96:781\u20139.","journal-title":"Am J Hematol"},{"key":"878_CR27","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/bjh.17084","volume":"191","author":"N Gangat","year":"2020","unstructured":"Gangat N, Morsia E, Foran JM, Palmer JM, Elliott MA, Tefferi A. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. Br J Haematol. 2020;191:e120\u20134.","journal-title":"Br J Haematol"},{"key":"878_CR28","doi-asserted-by":"publisher","first-page":"106456.","DOI":"10.1016\/j.leukres.2020.106456","volume":"98","author":"D Tremblay","year":"2020","unstructured":"Tremblay D, Feld J, Dougherty M, Czaplinska T, Sanchez G, Kremyanskaya M, et al. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm. Leuk Res. 2020;98:106456.","journal-title":"Leuk Res"},{"key":"878_CR29","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/ajh.26381","volume":"97","author":"AC King","year":"2022","unstructured":"King AC, Weis TM, Derkach A, Ball S, Pandey M, Mauro MJ, et al. Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. Am J Hematol. 2022;97:E7\u2013E10.","journal-title":"Am J Hematol"},{"key":"878_CR30","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","volume":"5","author":"L Masarova","year":"2021","unstructured":"Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, et al. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021;5:2156\u201364.","journal-title":"Blood Adv"},{"key":"878_CR31","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","volume":"2","author":"RK Rampal","year":"2018","unstructured":"Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, et al. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Adv. 2018;2:3572\u201380.","journal-title":"Blood Adv"},{"key":"878_CR32","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","volume":"4","author":"JO Mascarenhas","year":"2020","unstructured":"Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, et al. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020;4:5246\u201356.","journal-title":"Blood Adv"},{"key":"878_CR33","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","volume":"34","author":"P Bose","year":"2020","unstructured":"Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, et al. A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020;34:2489\u201392.","journal-title":"Leukemia"},{"key":"878_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-138437","volume":"136","author":"MW Drummond","year":"2020","unstructured":"Drummond MW, Gaskell C, Harrison C, Mead AJ, Yap C, Jackson AE, et al. Phazar: a phase Ib study to assess the safety and tolerability of ruxolitinib in combination with azacitidine in advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN [ISRCTN16783472]. Blood. 2020;136:2\u20133.","journal-title":"Blood"},{"key":"878_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/07853890.2022.2164611","volume":"55","author":"J Chen","year":"2023","unstructured":"Chen J, Wang K, Xiao Z, Xu Z. Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis. Ann Med. 2023;55:348\u201360.","journal-title":"Ann Med"},{"key":"878_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00388-x","volume":"10","author":"N Gangat","year":"2020","unstructured":"Gangat N, Tefferi A. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. Blood Cancer J. 2020;10:122.","journal-title":"Blood Cancer J"},{"key":"878_CR37","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1111\/bjh.16709","volume":"190","author":"AA Patel","year":"2020","unstructured":"Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, et al. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020;190:e48\u2013e51.","journal-title":"Br J Haematol"},{"key":"878_CR38","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","volume":"4","author":"HT Chifotides","year":"2020","unstructured":"Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, et al. Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020;4:5336\u201342.","journal-title":"Blood Adv"},{"key":"878_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00800-2","volume":"13","author":"R Ilyas","year":"2023","unstructured":"Ilyas R, McCullough K, Badar T, Patnaik MM, Alkhateeb H, Mangaonkar A, et al. CPX-351 (Vyxeos) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood Cancer J. 2023;13:26.","journal-title":"Blood Cancer J"},{"key":"878_CR40","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","volume":"123","author":"JE Lancet","year":"2014","unstructured":"Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239\u201346.","journal-title":"Blood"},{"key":"878_CR41","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6:3997\u20134005.","journal-title":"Blood Adv"},{"key":"878_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1:105\u201311.","journal-title":"Blood Adv"},{"key":"878_CR43","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","volume":"2","author":"TL Lasho","year":"2018","unstructured":"Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018;2:370\u201380.","journal-title":"Blood Adv"},{"key":"878_CR44","doi-asserted-by":"publisher","first-page":"107077.","DOI":"10.1016\/j.leukres.2023.107077","volume":"129","author":"W Aiman","year":"2023","unstructured":"Aiman W, Ali MA, Basit MA, Omar Z, Suleman M, Hassan M, et al. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: a systematic review of clinical trials. Leuk Res. 2023;129:107077.","journal-title":"Leuk Res"},{"key":"878_CR45","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386\u201398.","journal-title":"N Engl J Med"},{"key":"878_CR46","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722\u201331.","journal-title":"Blood"},{"key":"878_CR47","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1182\/blood-2022-164678","volume":"140","author":"M Bar-Natan","year":"2022","unstructured":"Bar-Natan M, Mascarenhas J, Gerds AT, Mesa R, Gupta V, Kremyanskaya M, et al. Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119. Blood. 2022;140:3988\u201390.","journal-title":"Blood"},{"key":"878_CR48","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/ajh.26349","volume":"96","author":"H Ali","year":"2021","unstructured":"Ali H, Bacigalupo A. 2021 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management. Am J Hematol. 2021;96:1532\u20138.","journal-title":"Am J Hematol"},{"key":"878_CR49","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ajh.26833","volume":"98","author":"G Orti","year":"2023","unstructured":"Orti G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M, et al. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2023;98:628\u201338.","journal-title":"Am J Hematol"},{"key":"878_CR50","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","volume":"6","author":"N Gagelmann","year":"2022","unstructured":"Gagelmann N, Wolschke C, Salit RB, Schroeder T, Ditschkowski M, Panagiota V, et al. Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis. Blood Adv. 2022;6:1222\u201331.","journal-title":"Blood Adv"},{"key":"878_CR51","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","volume":"56","author":"D McLornan","year":"2021","unstructured":"McLornan D, Eikema DJ, Czerw T, Kroger N, Koster L, Reinhardt HC, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transpl. 2021;56:2160\u201372.","journal-title":"Bone Marrow Transpl"},{"key":"878_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/bjh.15819","volume":"185","author":"N Kroger","year":"2019","unstructured":"Kroger N, Eikema DJ, Koster L, Beelen D, de Wreede LC, Finke J, et al. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. Br J Haematol. 2019;185:725\u201332.","journal-title":"Br J Haematol"},{"key":"878_CR53","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1182\/bloodadvances.2020002621","volume":"4","author":"V Gupta","year":"2020","unstructured":"Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4:4748\u201357.","journal-title":"Blood Adv"},{"key":"878_CR54","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/bmt.2014.31","volume":"49","author":"X Cahu","year":"2014","unstructured":"Cahu X, Chevallier P, Clavert A, Suarez F, Michallet M, Vincent L, et al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transpl. 2014;49:756\u201360.","journal-title":"Bone Marrow Transpl"},{"key":"878_CR55","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3324\/haematol.2013.094284","volume":"99","author":"F Lussana","year":"2014","unstructured":"Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, et al. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99:916\u201321.","journal-title":"Haematologica"},{"key":"878_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","volume":"20","author":"H Alchalby","year":"2014","unstructured":"Alchalby H, Zabelina T, Stubig T, van Biezen A, Bornhauser M, Di Bartolomeo P, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2014;20:279\u201381.","journal-title":"Biol Blood Marrow Transpl"},{"key":"878_CR57","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/bjh.17423","volume":"193","author":"MV Shah","year":"2021","unstructured":"Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, et al. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021;193:1004\u20138.","journal-title":"Br J Haematol"},{"key":"878_CR58","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","volume":"121","author":"JA Kennedy","year":"2013","unstructured":"Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood. 2013;121:2725\u201333.","journal-title":"Blood"},{"key":"878_CR59","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.bbmt.2020.02.019","volume":"26","author":"M Ruggiu","year":"2020","unstructured":"Ruggiu M, Cassinat B, Kiladjian JJ, Raffoux E, Giraudier S, Robin M, et al. Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation. Biol Blood Marrow Transpl. 2020;26:1160\u201370.","journal-title":"Biol Blood Marrow Transpl"},{"key":"878_CR60","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"878_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2022-159962","volume":"140","author":"M Stelljes","year":"2022","unstructured":"Stelljes M, Middeke JM, Bug G, Wagner E-M, Mueller LP, Christoph S, et al. In patients with relapsed\/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by Allo-HCT: results from the randomized phase III ASAP trial. Blood. 2022;140:9\u201311.","journal-title":"Blood"},{"key":"878_CR62","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023;141:2901\u201311.","DOI":"10.1182\/blood.2023019630"},{"key":"878_CR63","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/bloodadvances.2022007230","volume":"6","author":"G Barosi","year":"2022","unstructured":"Barosi G, Gale RP. Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story. Blood Adv. 2022;6:2331\u20133.","journal-title":"Blood Adv"},{"key":"878_CR64","doi-asserted-by":"publisher","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A phase Ib\/II study of ivosidenib with venetoclax +\/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0205.","DOI":"10.1158\/2643-3230.BCD-22-0205"},{"key":"878_CR65","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/blood.2021011094","volume":"141","author":"H Kuusanmaki","year":"2023","unstructured":"Kuusanmaki H, Dufva O, Vaha-Koskela M, Leppa AM, Huuhtanen J, Vanttinen I, et al. Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141:1610\u201325.","journal-title":"Blood"},{"key":"878_CR66","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"29","author":"NM Kroger","year":"2015","unstructured":"Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group. Leukemia. 2015;29:2126\u201333.","journal-title":"Leukemia"},{"key":"878_CR67","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/ajh.26654","volume":"97","author":"J Perram","year":"2022","unstructured":"Perram J, Ross DM, McLornan D, Gowin K, Kroger N, Gupta V, et al. Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis. Am J Hematol. 2022;97:1464\u201377.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00878-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T23:30:40Z","timestamp":1689636640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00878-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00878-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"23 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}